Simultaneous analysis of the of levamisole with triclabendazole in pharmaceuticals through developing TLC and HPLC–PDA chromatographic techniques and their greenness assessment using GAPI and AGREE methods

Table 8 Assessment of LEVA and TCBZ in Martibendazene^® oral suspension by the developed TLC method and outcomes of standard addition technique

Product	Drugs	Standard addition
Martibendazene® Suspension^a		Claimed taken	Added	Total Found^b	Standard found^b	Recovery %^b
	Levamisole	4	–-	3.99	–-	99.87
		4	2	5.98	1.99	99.57
		4	4	8.03	4.04	100.99
		4	6	9.98	5.99	99.80
			Mean ± SD			100.12 ± 0.76
	Triclabendazole	6	–-	6.02	–-	100.32
		6	2	8	1.98	98.79
		6	6	12.01	5.99	99.81
		6	8	14.06	8.04	100.46
			Mean ± SD			99.69 ± 0.85

^a Labeled to have 75 mg LEVA and 120 mg TCBZ
^b Average of three measurements
The bold values express (Mean) which is the average of recovery percentage and (SD) which is the standard deviation of recovery percentage.

ISSN: 2661-801X